DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day Dexcom G7 integrated continuous glucose monitor (CGM) in ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use glucose ...

The government of Saskatchewan has expanded public coverage for continuous glucose monitoring (CGM) systems. The expansion, which now provides full coverage for CGMs for young adults ages 18 to 25 and ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

"We conclude that the Dexcom 15-day G7 CGM is accurate and safe for use up to 15.5 days in adults with diabetes with a 27-minute warm-up," stated the investigators.

Per the terms of the agreement, Nanowear will use glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) synchronously alongside Nanowear’s previously FDA-cleared cardiovascular ...